The Effect of Intraoperative Labetalol on Time to Discharge

The Effect of Intraoperative Labetalol on Time to Discharge and Hemodynamic Stability in Laparoscopic Cholecystectomy

Patients coming for surgery often receive opioid medications, like fentanyl, to treat pain. Opioids however have many unpleasant side effects including nausea and vomiting, itching, sedation, and decreased breathing. During laparoscopic surgery increases in heart and blood pressure are often attributed to pain. It has been shown that by treating these changes with medications such as esmolol, instead of opioids, side effects and time to discharge from hospital can be reduced. Labetalol is a drug that is similar to esmolol but may have advantages over it. It is more effective at controlling both heart rate and blood pressure and it is easier and less costly to use. This study is investigating labetalol in patients having laparoscopic gallbladder surgery and comparing it to esmolol and fentanyl. Patients will be treated with one of these drugs during surgery to control heart rate and blood pressure and the effects on time to discharge, pain scores, frequency of side effects, and narcotic requirements will be observed in the recovery room. It is thought that labetalol will be shown to be as effective as esmolol and that both drugs that minimize fentanyl will show reduced time to discharge, fewer side effects, and effective treatment of heart rate and blood pressure.

Study Overview

• Status: Completed
• Conditions: Heart Rate; Bloodpressure
• Intervention / Treatment: Drug: Esmolol; Other: 1 ml saline infusion; Drug: Labetalol; Other: saline infusion; Drug: Fentanyl

• Study Type: Interventional
• Enrollment (Actual): 172
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Kingston, Ontario, Canada, K7L 2V7
      • Queen's University, Department of Anesthesiology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• scheduled to undergo elective ambulatory laparoscopic cholecystectomy under general anesthesia
• American Society of Anesthesiologist's Status ASA) 1-3
• able to understand and sign informed consent

Exclusion Criteria:

• known allergy to any of the study medications including beta blockers, fentanyl, acetaminophen, non-steroidal anti-inflammatories or local anesthetics
• chronic use of beta-adrenergic receptor antagonists or opioids
• conversion to open cholecystectomy
• History of renal, hepatic or cardiac failure, reactive airway disease
• Medical history that in the investigator's judgement would interfere with the protocol or assessments
• Unable to understand pain assessment
• Failure to give informed consent
• pregnant or breastfeeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Esmolol; Esmolol infusion and 1 ml saline infusion	Drug: Esmolol; Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.; Other: 1 ml saline infusion; Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
Experimental: Labetalol; Labetalol Bolus and saline infusion	Drug: Labetalol; Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.; Other: saline infusion; An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Active Comparator: Fentanyl; Fentanyl Bolus and saline infusion	Other: saline infusion; An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.; Drug: Fentanyl; Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of stay in the post-anesthesia care unit (PACU)	time from arrival in PACU after surgery until discharge from PACU	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intraoperative Heart Rate (HR)	heart rate (beats per min.)	intraoperatively-from anesthesia induction to the surgery completion (wound closure) -approximately 45 min.
Intraoperative mean arterial pressure (MAP)	blood pressure (mmHg)	intraoperatively-from anesthesia induction to the surgery completion (wound closure)-approximately 45 min.
postoperative nausea and vomiting (PONV) in PACU	incidence of nausea and vomiting	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
pain scores	pain scores visual analogue scale (VAS)	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
fentanyl required	total fentanyl required mcg	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
adverse effects	Any reported adverse effects or complications	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
postoperative heart rate	heart rate (beats per min)	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
postoperative mean arterial pressure (MAP)	blood pressure (mmHg)	The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).

Collaborators and Investigators

• Sponsor: Dr. Robert Tanzola
• Investigators: Principal Investigator: Robert Tanzola, MD, FRCPC, Queen's University-Anesthesiology

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (Actual): January 1, 2019
• Study Completion (Actual): January 1, 2019

Study Registration Dates

• First Submitted: December 8, 2016
• First Submitted That Met QC Criteria: December 15, 2016
• First Posted (Estimate): December 20, 2016

Study Record Updates

• Last Update Posted (Actual): February 13, 2020
• Last Update Submitted That Met QC Criteria: February 11, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Central Nervous System Depressants; Autonomic Agents; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Analgesics, Opioid; Narcotics; Adjuvants, Anesthesia; Sympathomimetics; Adrenergic beta-1 Receptor Antagonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Fentanyl; Labetalol; Esmolol
• Other Study ID Numbers: ANAE-219-12